Dolby Laboratories (NYSE:DLB) Stock Price Breaks Below 200-Day Moving Average After Analyst Downgrade

Dolby Laboratories (NYSE:DLB – Get Free Report) passed below its 200-day moving average during trading on Tuesday after Rosenblatt Securities lowered their price target on the stock from $85.00 to $80.00. The stock has a 200-day moving average of $59.40 and traded as low as $58.25. Rosenblatt Securities currently has a buy rating on the stock. Dolby Laboratories shares last traded at $58.6010, with a volume of 4,334,134 shares traded.

A number of other brokerages also recently issued reports on DLB. Weiss Ratings raised Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, September 9th. Wall Street Zen cut shares of Dolby Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Zacks Research upgraded shares of Dolby Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

Read Our Latest Report on DLB

Insider Activity

In related news, SVP John Couling sold 7,667 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $58.78, for a total value of $450,666.26. Following the completion of the sale, the senior vice president directly owned 166,803 shares of the company’s stock, valued at $9,804,680.34. This represents a 4.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ryan Nicholson sold 1,183 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $65.28, for a total value of $77,226.24. Following the transaction, the chief accounting officer owned 34,453 shares in the company, valued at $2,249,091.84. This represents a 3.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,517 shares of company stock valued at $995,963 over the last three months. Company insiders own 37.93% of the company’s stock.

More Dolby Laboratories News

These are some of the DLB news items that stood out recently:

  • Positive Sentiment: Fiscal Q4 revenue rose 21.7% year over year to $373.5 million, slightly exceeding estimates, while EPS of $1.25 also topped consensus. Dolby Laboratories fiscal 2026 results
  • Neutral Sentiment: FY2027 EPS guidance of $4.27–$4.42 brackets the $4.34 consensus estimate. Rosenblatt lowered its price target from $85 to $80 but retained a Buy rating. Rosenblatt rating and target
  • Negative Sentiment: Near-term guidance was notably weak: Q1 FY2027 revenue of $285–$305 million is well below the $358.3 million consensus, and EPS guidance of $0.41–$0.56 trails the $1.06 estimate. FY2027 revenue guidance of $1.4 billion also falls short of the $1.5 billion expectation, raising concerns that the strong quarter may not carry forward. Dolby guidance report

Hedge Funds Weigh In On Dolby Laboratories

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in shares of Dolby Laboratories during the second quarter worth approximately $253,289,000. First Trust Advisors LP raised its position in Dolby Laboratories by 6.2% in the 3rd quarter. First Trust Advisors LP now owns 2,872,446 shares of the electronics maker’s stock valued at $168,814,000 after purchasing an additional 166,942 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Dolby Laboratories by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,321,407 shares of the electronics maker’s stock valued at $79,357,000 after purchasing an additional 83,835 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Dolby Laboratories in the 3rd quarter valued at $40,429,000. Finally, Advisors Asset Management Inc. acquired a new stake in Dolby Laboratories during the 3rd quarter worth $34,670,000. 58.56% of the stock is currently owned by hedge funds and other institutional investors.

Dolby Laboratories Trading Down 4.2%

The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 24.94 and a beta of 0.79. The stock’s 50 day moving average is $60.90 and its two-hundred day moving average is $59.40.

Dolby Laboratories (NYSE:DLB – Get Free Report) last issued its quarterly earnings data on Tuesday, November 17th. The electronics maker reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.05. The company had revenue of $373.54 million for the quarter, compared to the consensus estimate of $372.76 million. Dolby Laboratories had a net margin of 16.70% and a return on equity of 11.08%. Dolby Laboratories’s revenue for the quarter was up 21.7% on a year-over-year basis. During the same period last year, the firm posted $0.99 EPS. Dolby Laboratories has set its Q1 2027 guidance at 0.410-0.560 EPS and its FY 2027 guidance at 4.270-4.420 EPS. On average, sell-side analysts predict that Dolby Laboratories will post 3.23 EPS for the current year.

Dolby Laboratories announced that its Board of Directors has authorized a stock repurchase program on Thursday, July 30th that allows the company to repurchase $350 million in outstanding shares. This buyback authorization allows the electronics maker to purchase up to 7% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.

About Dolby Laboratories

(Get Free Report)

Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.

See Also

Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.